First Children To Begin Treatment, Medicaid Covers Ryoncil
Filed with ASX · · 2 pages · English
Watch Mesoblast's latest callMesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mesoblast (ASX:MSB) Q4 2026 Earnings CallStory so far
Earlier from Mesoblast
- First Three Children to Commence Treatment With Ryoncil®
- Ryoncil Is Now Available For Purchase In The United States
- Ryoncil® Product Information Now Available in All Four Major Drug Pricing Compendia in United States
- Mesoblast CEO to Deliver Featured Presentation at ISCT North America Virtual Town Hall
- Mesoblast Added to S&P/ASX 200 INDEX
Later from Mesoblast
- Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure
- Mesoblast Allogeneic Cell Therapy Products Are Designated ‘U.S. Country of Origin’ and Not Subject to U.S. Tariffs
- Mesoblast Cell Therapy Products Not Subject to U.S. Tariffs
- Mesoblast Extends Payer Coverage For Ryoncil® to Over 100 Million US Lives
- Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast